Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease;Anti-TNF-antikörper zur therapie von entzündlichen darmstenosen bei morbus Crohn

Zeitschrift fur Gastroenterologie

Volumn 41, Issue 1, 2003, Pages 11-17

  Holtmann, M ^a   Wanitschke, R ^a   Helisch, A ^a   Bartenstein, P ^a   Galle, P R ^a   Neurath, M ^a  

^a NONE

Author keywords

Crohn's disease; Infliximab (remicade); Stenosing

Indexed keywords

INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST RADIOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; INFLAMMATORY INFILTRATE; INTESTINE STENOSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 0037255111     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-36677     Document Type: Article

References (26)

1. Stange EF. Colitis ulcerosa - Morbus Crohn Bremen: Uni-Med Verlag 1999
2. Neurath MF, Schürmann G. Zur Immunpathogenese der chronisch entzündlichen Darmerkrankungen Der Chirurg 2000; 71: 30-40
3. Holtmann M, Schütz M, Galle PR et al. Functional Relevance of soluble and transmembrane TNF and TNF-Signaltransduction in Gastrointestinal Diseases With Special Reference to Inflammatory Bowel Diseases Z Gastroenterologie 2002: 40: 587-600
4. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 1999; 340: 1398-1405
5. Ewe K, Press AG, Singe CC et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease Gastroenterology 1993; 105: 367-372
6. Candy S, Wright J, Gerber M et al. A controlled double blind study of azathioprine in the management of Crohn's disease Gut 1995; 37: 674-678
7. O'Donoghue DP, Dawson AM, Powell-Tuck J et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease Lancet 1978; 2: 955-957
8. Neurath MF, Wanitschke R, Peters M et al. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease Gut 1999; 44: 625-628
9. SE Neurath MF. Evidenzbasierte Immunsuppression bei chronisch entzündlichen Darmerkrankungen Deutsches Ärzteblatt 2000; 97: A: A1977-1986
10. Sandborn WJ, Sutherland LR, Pearson DC et al. Azathioprine or 6-Mercaptopurine for inducing remission of Crohn's disease Edited by Library TC 1999; Vol 1
11. Knight DM,Trinh H, LeJ et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Mol Immunol 1993; 30: 1443-1453
12. Scallon BJ, Moore MA, Trinh H et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 1995; 7: 251-259
13. van Dullemen HM, van Deventer SJ, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology 1995; 109: 129-135
14. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group N Engl J Med 1997; 337: 1029-1035
15. Ricart E, Panaccione R, Loftus EV et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients Am J Gastroenterol 2001: 96: 722-729
16. Luegering A, Schmidt M, Luegering N et al. Infliximab induces apoptosis in monocytes from patients with chronic active crohn's disease by using a caspase-dependent pathway Gastroenterology 2001; 121: 1145-1157
17. Schunk K, Kern A, Oberholzer K et al. Hydro-MRI in Crohn's disease: appraisal of disease activity Invest Radiol 2000; 35: 431-437
18. Schunk K, Kern A, Heussel CP et al. Assessment of inflammatory activity in Crohn disease with hydro-MRI Röfo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 2000; 172: 153-160
19. Bartenstein P, Weindl A, Spiegel S et al. Central motor processing in Huntington's disease. A PET study Brain 1997; 120: 1553-1567
20. Neurath MF, Vehling K, Schunk K et al. Non-invasive assessment of Crohn's disease activity: a comparison of 18F-fluoro-deoxy-glucosepositron emission tomography hydromagnetic resonance imaging and granulocyte scintigraphy with labelled antibodies Am J Gastroenterol in press
21. Stange EF, Schreiber S, Raedler A et al. Therapy of Crohn diseases - results of a Consensus Conference of the German Society of Digestive and Metabolic Diseases Z Gastroenterol 1997; 35: 541-554
22. Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA et al. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment Am J Gastroenterol 2001; 96: 1665
23. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 2001; 345: 1098-1104
24. Bickston SJ, Lichtenstein GR, Arseneau KO et al. The relationship between infliximab treatment and lymphoma in Crohn's disease Gastroenterology 1999; 117: 1433-1437
25. Aithal GP, Mansfield JC. the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment Aliment Pharmacol Ther 2001; 15: 1101-1108
26. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 2002; 359: 1541-1549